The leukocyte immunoglobulin-like receptor B2 (LILRB2), also known as ILT4, is an immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptor that is widely expressed on immunosuppressive myeloid cells in the tumor microenvironment.
Curevac NV and The University of Texas MD Anderson Cancer Center have entered into a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
A research team at University of California, Los Angeles (UCLA), funded by Cancervax Inc., has created a promising new bispecific antibody vaccine for treating recurrent Ewing sarcoma.
Researchers from Abbvie Inc. recently presented preclinical data for ABBV-706, an SEZ6-targeted topoisomerase 1 (TOP1) inhibitor antibody-drug conjugate (ADC), being developed for the treatment of small-cell lung cancer (SCLC) and other SEZ6-expressing cancers.
Proviva Therapeutics Ltd. scientists hypothesized that both the activation of IL-2 receptor (IL-2R) and the blockade of programmed cell death protein 1 (PD-1) are complementary and potentially synergistic as a combination therapy for treating cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described Toll-like receptor 7 (TLR7) and/or TLR8 agonists and their immunostimulatory antibody conjugates (ISACs) consisting of antibodies covalently linked to TLR7 and/or TLR8 agonists through cleavable or uncleavable linkers.
The overexpression of transferrin receptor 1 (TfR1) has been reported in several cancer types but is also expressed in normal cell types such as erythroblasts. On the other hand, epidermal growth factor receptor (EGFR) is highly expressed in epithelial carcinomas.
A team from GC Cell Corp. reported preclinical data on GL-205, a novel allogeneic anti-CD5 CAR-NK being developed for the treatment of T-cell malignancies. GL-205 was developed using cord blood-derived NK cells that were genetically modified to express CD5-directed CAR and simultaneously produce IL-15 to support NK cell survival and proliferation.
Researchers from Beigene (Beijing) Co. Ltd. have disclosed preclinical data for BGB-B167, a first-in-class immunoglobulin G (IgG)-based bispecific antibody (bsAb) targeting 4-1BB and CEA, being developed for the treatment of advanced or metastatic solid tumors.
RSS
